These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 12016549)

  • 1. Drugs and steatohepatitis.
    Farrell GC
    Semin Liver Dis; 2002; 22(2):185-94. PubMed ID: 12016549
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fatty liver and drugs.
    Grieco A; Forgione A; Miele L; Vero V; Greco AV; Gasbarrini A; Gasbarrini G
    Eur Rev Med Pharmacol Sci; 2005; 9(5):261-3. PubMed ID: 16237810
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Drug-induced Nonalcoholic Steatohepatitis].
    Miyamura M; Yokota J; Saibara T
    Yakugaku Zasshi; 2016; 136(4):579-82. PubMed ID: 27040342
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Etiopathogenesis of nonalcoholic steatohepatitis.
    Chitturi S; Farrell GC
    Semin Liver Dis; 2001; 21(1):27-41. PubMed ID: 11296694
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug Induced Steatohepatitis: An Uncommon Culprit of a Common Disease.
    Rabinowich L; Shibolet O
    Biomed Res Int; 2015; 2015():168905. PubMed ID: 26273591
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug-induced toxicity on mitochondria and lipid metabolism: mechanistic diversity and deleterious consequences for the liver.
    Begriche K; Massart J; Robin MA; Borgne-Sanchez A; Fromenty B
    J Hepatol; 2011 Apr; 54(4):773-94. PubMed ID: 21145849
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Cirrhosis with non alcoholic steatohepatitis: role of tamoxifen].
    Dray X; Tainturier MH; De La Lande P; Marty O; Mallet L
    Gastroenterol Clin Biol; 2000 Nov; 24(11):1122-3. PubMed ID: 11139682
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of fatty acids in the pathogenesis of obesity and fatty liver: impact of bariatric surgery.
    Verna EC; Berk PD
    Semin Liver Dis; 2008 Nov; 28(4):407-26. PubMed ID: 18956297
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug-induced steatohepatitis.
    Stravitz RT; Sanyal AJ
    Clin Liver Dis; 2003 May; 7(2):435-51. PubMed ID: 12879993
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Drug-induced NASH].
    Saibara T; Onishi S
    Nihon Rinsho; 2006 Jun; 64(6):1100-5. PubMed ID: 16768116
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CYP17 polymorphism as a risk factor of tamoxifen-induced hepatic steatosis in breast cancer patients.
    Ohnishi T; Ogawa Y; Saibara T; Nishioka A; Kariya S; Fukumoto M; Onishi S; Yoshida S
    Oncol Rep; 2005 Mar; 13(3):485-9. PubMed ID: 15706422
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nonalcoholic fatty liver disease: from steatosis to cirrhosis.
    Farrell GC; Larter CZ
    Hepatology; 2006 Feb; 43(2 Suppl 1):S99-S112. PubMed ID: 16447287
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acarbose is a promising therapeutic strategy for the treatment of patients with nonalcoholic steatohepatitis (NASH).
    Yamagishi S; Nakamura K; Inoue H
    Med Hypotheses; 2005; 65(2):377-9. PubMed ID: 15922116
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence and risk factors for non-alcoholic steatohepatitis: prospective study of 5408 women enrolled in Italian tamoxifen chemoprevention trial.
    Bruno S; Maisonneuve P; Castellana P; Rotmensz N; Rossi S; Maggioni M; Persico M; Colombo A; Monasterolo F; Casadei-Giunchi D; Desiderio F; Stroffolini T; Sacchini V; Decensi A; Veronesi U
    BMJ; 2005 Apr; 330(7497):932. PubMed ID: 15746106
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities.
    Sanyal AJ; Campbell-Sargent C; Mirshahi F; Rizzo WB; Contos MJ; Sterling RK; Luketic VA; Shiffman ML; Clore JN
    Gastroenterology; 2001 Apr; 120(5):1183-92. PubMed ID: 11266382
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular mechanisms of steatosis in nonalcoholic fatty liver disease.
    Pettinelli P; Obregón AM; Videla LA
    Nutr Hosp; 2011; 26(3):441-50. PubMed ID: 21892559
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Roles of adipose restriction and metabolic factors in progression of steatosis to steatohepatitis in obese, diabetic mice.
    Larter CZ; Yeh MM; Van Rooyen DM; Teoh NC; Brooling J; Hou JY; Williams J; Clyne M; Nolan CJ; Farrell GC
    J Gastroenterol Hepatol; 2009 Oct; 24(10):1658-68. PubMed ID: 19788606
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Uncoupling protein-2 (UCP2) induces mitochondrial proton leak and increases susceptibility of non-alcoholic steatohepatitis (NASH) liver to ischaemia-reperfusion injury.
    Serviddio G; Bellanti F; Tamborra R; Rollo T; Capitanio N; Romano AD; Sastre J; Vendemiale G; Altomare E
    Gut; 2008 Jul; 57(7):957-65. PubMed ID: 18308829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nonalcoholic steatohepatitis and insulin resistance: interface between gastroenterologists and endocrinologists.
    Scheen AJ; Luyckx FH
    Acta Clin Belg; 2003; 58(2):81-91. PubMed ID: 12836490
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Insulin resistance accelerates a dietary rat model of nonalcoholic steatohepatitis.
    Ota T; Takamura T; Kurita S; Matsuzawa N; Kita Y; Uno M; Akahori H; Misu H; Sakurai M; Zen Y; Nakanuma Y; Kaneko S
    Gastroenterology; 2007 Jan; 132(1):282-93. PubMed ID: 17241878
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.